Indegene Ltd
Incorporated in 1998, Indegene Ltd provides
solutions consisting of analytics, technology
and commercial, medical, regulatory and
safety services to life science and health
care organizations[1]
- Market Cap ₹ 14,523 Cr.
- Current Price ₹ 604
- High / Low ₹ 737 / 469
- Stock P/E 35.7
- Book Value ₹ 109
- Dividend Yield 0.00 %
- ROCE 24.2 %
- ROE 20.1 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 67.2% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 24.1%
Cons
- Working capital days have increased from 97.7 days to 208 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Miscellaneous
Part of BSE Healthcare Nifty 500 BSE SmallCap BSE Allcap Nifty MidSmallcap 400
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
553 | 643 | 966 | 1,665 | 2,306 | 2,590 | 2,839 | |
511 | 499 | 736 | 1,378 | 1,910 | 2,084 | 2,305 | |
Operating Profit | 42 | 144 | 230 | 287 | 396 | 505 | 534 |
OPM % | 8% | 22% | 24% | 17% | 17% | 20% | 19% |
7 | -102 | -3 | -21 | 58 | 79 | 107 | |
Interest | 6 | 9 | 7 | 6 | 31 | 49 | 22 |
Depreciation | 17 | 19 | 26 | 33 | 60 | 76 | 80 |
Profit before tax | 26 | 14 | 195 | 226 | 363 | 459 | 539 |
Tax % | 45% | 191% | 23% | 28% | 27% | 27% | 25% |
14 | -12 | 149 | 163 | 266 | 337 | 407 | |
EPS in Rs | 89.98 | -40.20 | 951.96 | 937.73 | 11.99 | 15.14 | 16.95 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 12% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 35% |
3 Years: | 19% |
TTM: | 10% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 67% |
3 Years: | 29% |
TTM: | 21% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 15% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 28% |
3 Years: | 24% |
Last Year: | 20% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
Equity Capital | 0.31 | 0.31 | 0.31 | 0.35 | 44 | 44 | 48 |
Reserves | 73 | -105 | 324 | 764 | 1,020 | 1,385 | 2,568 |
147 | 483 | 51 | 66 | 502 | 490 | 102 | |
108 | 222 | 220 | 524 | 638 | 627 | 609 | |
Total Liabilities | 329 | 600 | 596 | 1,353 | 2,204 | 2,546 | 3,326 |
104 | 119 | 86 | 138 | 664 | 646 | 678 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
Investments | 0 | 13 | 0 | 120 | 614 | 796 | 1,290 |
225 | 468 | 510 | 1,096 | 926 | 1,103 | 1,355 | |
Total Assets | 329 | 600 | 596 | 1,353 | 2,204 | 2,546 | 3,326 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
65 | 22 | 172 | 297 | 130 | 508 | 442 | |
-18 | -16 | -81 | -158 | -896 | -326 | -683 | |
-21 | 136 | -132 | 233 | 333 | -66 | 288 | |
Net Cash Flow | 25 | 143 | -40 | 373 | -433 | 115 | 47 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
Debtor Days | 60 | 127 | 108 | 97 | 102 | 91 | 81 |
Inventory Days | |||||||
Days Payable | |||||||
Cash Conversion Cycle | 60 | 127 | 108 | 97 | 102 | 91 | 81 |
Working Capital Days | 23 | 64 | 53 | 16 | 45 | 40 | 208 |
ROCE % | 37% | 55% | 46% | 33% | 29% | 24% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Directorate
54s - Re-appointment of Dr. Georgia Nikolakopoulou Papathomas as Independent Director subject to approval of shareholders at the ensuing Annual General Meeting.
- Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 8m
-
Record Date For The Purpose Of Dividend
13m - AGM set for June 26, 2025; final dividend ₹2/share; re-appointment of independent director approved.
-
Intimation Of Outcome Of Board Meeting
19m - AGM on June 26, ₹2 final dividend, and re-appointment of independent director Dr. Papathomas.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
1d - Schedule of investor meetings on May 29-30, 2025, with no price sensitive info shared.
Concalls
-
May 2025Transcript PPT REC
-
Mar 2025TranscriptNotesPPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Aug 2024TranscriptNotesPPT
-
Jun 2024TranscriptPPTREC
Business Overview:[1]
IL is a digital-first healthcare and technology company. It helps bio pharmaceutical, emerging biotech and medical device companies to develop products and get them to market. Company brings together healthcare domain expertise, technology and an agile operating model to provide diverse solutions for patients and physicians.